Department of Pathology, Hospital of the University of Pennsylvania, 6 Founders, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
Endocr Pathol. 2018 Dec;29(4):317-323. doi: 10.1007/s12022-018-9540-9.
There is evidence that programmed death-ligand 1 (PD-L1) is expressed by thyroid follicular epithelium in thyroiditis, but the role of PD-L1 in papillary thyroid carcinoma (PTC) is poorly understood. We aimed to determine whether (1) the presence of background chronic lymphocytic thyroiditis (CLT) or Hashimoto thyroiditis (HT) influenced the expression of PD-L1 in benign follicular epithelium or in PTC and (2) if PD-L1 expression in PTC persisted with lymph node metastasis. We performed immunohistochemistry (IHC) for PD-L1 on formalin-fixed paraffin-embedded tissues. We first studied five cases of unremarkable thyroid, five cases of CLT, and five cases of HT without carcinoma. We subsequently performed PD-L1 IHC on ten cases of PTC arising in normal thyroid, ten cases of PTC arising in CLT, and ten cases of PTC arising in HT. Whenever available, we evaluated corresponding synchronous lymph node metastases from all cases for PD-L1 expression. PD-L1 expression was increased (10-90%) in all five cases of HT, only minimal expressed (1-5%) in two of five cases of CLT, and not expressed in five cases of unremarkable thyroid. PTC arising in normal thyroid or CLT nearly uniformly lacked PD-L1 expression. In contrast, PTC arising in HT demonstrated significant PD-L1 expression, which persisted in corresponding lymph node metastases. Background non-neoplastic follicular epithelium in the HT cases also demonstrated PD-L1 expression. Thyroid follicular epithelium in HT demonstrates increased PD-L1 expression, and PTC arising in a background of HT shows increased PD-L1 expression, which is retained with metastasis.
有证据表明,程序性死亡配体 1(PD-L1)在甲状腺炎的甲状腺滤泡上皮中表达,但 PD-L1 在甲状腺乳头状癌(PTC)中的作用知之甚少。我们旨在确定(1)背景慢性淋巴细胞性甲状腺炎(CLT)或桥本甲状腺炎(HT)的存在是否会影响良性滤泡上皮或 PTC 中 PD-L1 的表达,以及(2)如果 PTC 中 PD-L1 的表达是否会随着淋巴结转移而持续存在。我们对福尔马林固定石蜡包埋组织进行了 PD-L1 的免疫组织化学(IHC)检测。我们首先研究了五例无明显异常的甲状腺、五例 CLT 和五例无癌 HT。随后,我们对十例起源于正常甲状腺的 PTC、十例起源于 CLT 的 PTC 和十例起源于 HT 的 PTC 进行了 PD-L1 IHC。只要有可能,我们评估了所有病例相应的同步淋巴结转移中 PD-L1 的表达情况。HT 的所有五例病例中 PD-L1 表达均增加(10-90%),CLT 的五例病例中仅有两例表达轻微(1-5%),五例无明显异常的甲状腺中均未表达。起源于正常甲状腺或 CLT 的 PTC 几乎均无 PD-L1 表达。相比之下,起源于 HT 的 PTC 显示出明显的 PD-L1 表达,这种表达在相应的淋巴结转移中得以保留。HT 病例中的非肿瘤性滤泡上皮也表现出 PD-L1 表达。HT 中的甲状腺滤泡上皮表达 PD-L1 增加,而 HT 背景下发生的 PTC 显示 PD-L1 表达增加,并在转移时保留。